Oral rinse compositions.
Abstract
Mouthrinses containing sanguinarine of superior efficacy and increased uptake into dental plaque are attained by the development of stable mouthrinses adjusted to a pH in the range of 4.0 to 5.6, preferably about 4.5. Compositions may contain a zinc salt as an optional ingredient. Various types of buffer systems are described.
Term
Term ended
Projected expiry passed 12 March 2010, 16.5 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
12 claims: 8 independent, 4 dependent
- 1An oral composition containing benzophenanthridine alkaloid characterized in that it is stabilized by the presence of an orally acceptable buffer system buffered to acid pH.
- 3A stable oral rinse composition comprising from about 0.01 to 0.2% by weight of benzophenanthridine alkaloid in an aqueous solution and a buffer system in a quantity sufficient to adjust the pH of said composition to a pH in the range of 4.0 to 5.6.
- 11A composition as claimed in any one of Claims 1 to 10 characterized in that the said alkaloid is selected from the group consisting of water soluble salts of sanguinarine, chelerythrine, sanguilutine, chelilutine, chelirubine, and sanguirubine;and in that the said buffer system is selected from (a) sodium citrate and citric acid, (b) sodium acetate and acetic acid, and (c) sodium tartrate and tartaric acid.
- 12A composition as claimed in any one of the preceding claims in which any surface active agent present if a nonionic block copolymer of polyoxyethylene and polyoxypropylene has an unsaturation of less than 45 meq/mg.
Independent claims8
43 paragraphs in 4 sections, as filed
This invention relates to novel sanguinarine mouthrinses stabilized at a pH which provides improved uptake of sanguinaria into plaque and improved protection against acid production by salivary bacteria after a glucose challenge.
Sanguinarine canadensis is known as Bloodroot, Puccoon, Tetterwort, etc. and is a herb native to North America. The plant and its juices have been used for various purposes during pre-history as well as written history. It has been used as a natural historic folk remedy medicine. The plant has been generally used whole either undried (fresh) or dried. The usual procedure is to powder the dried plant and mix it with a carrier. This folk remedy has been tried for such things as asthma, bronchitis, dysentery, ringworm, and a substantial list of other ailments. Sanguinarine, chelerythine, and other benzophenanthridine alkaloids are known alkaloids defined as isoquinolines. Plant sources for these alkaloids fall into various species, the <u style="single">Papaveraceae</u>, <u style="single">Fumariaceae</u>, and <u style="single">Rutaceae</u> families. Recoveries of these alkaloids from <u style="single">Sanguinaria</u><u style="single">Canadensis L.</u> and <u style="single">Macleaya</u> species are described in U.S. Patents 4,145,412; 4,406,881; 4,517,172; 4,590,061; 4,599,228; 4,683,133; 4,689,216; 4,767,861; and 4,769,452. Production of these alkaloids from plant tissue culture has been described in <u style="single">Plant Cell Reports</u> (1988) 7:410-413.
Purification of the Benzophenanthridine alkaloids into individual alkaloids without using known chromatographic methods is also described in the foregoing U.S. Patents.
The use of an extract containing these benzophenanthridine alkaloids from Sanguinaria Canadensis as an ingredient in an oral cleaning preparation is also disclosed in the foregoing U.S. Patents.
Other uses for the extract of Sanguinaria Canadensis L. are reported as a plaque disclosing agent in U.S. Patents 4,517,172 and 4,590,061.
It is known that mouthrinses and dentifrices containing sanguinaria extract are effective anti-plaque and anti-gingivitis agents. They are also effective against oral malodor and calculus.
Early patents, U.S. Patent 209,331 and U.S. Patent 2,344,830 describe the use of sanguinaria in combination with zinc chloride. Although there is no indication that zinc chloride is needed to maintain efficacy, sanguinaria extract is typically used in combination with zinc chloride or other metallic salts, such as stannous chloride, in dentifrices, as in U.S. Patent 4,689,216. When sanguinaria extract is combined with zinc chloride in a mouthrinse vehicle the pH is usually adjusted to 3. Prior art teaches that zinc mouthrinses are adjusted to pH 3 to prevent the formation of insoluble zinc compounds such as zinc hydroxide and zinc oxychloride. See U.S. Patent 4,289,755. In addition, solutions of sanguinaria are acidified to prevent the formation of psuedo base forms of the benzophenanthridine alkaloids present in the extract. Pseudo base forms of the alkaloids present in the extract begin to form at approximately pH 5.6 (Jones, et al. J. of Natural Products, Vol. 49, No. 6, pp.1109-1111, Nov.-Dec., 1986).
In addition, the extract was adjusted to a pH of 3 to maintain chemical stability of the extract and prevent the formation of brownish to black precipitates which are assumed to be due to the condensation of tannins and to the presence of lignin-like material in the extract. It has been found that 1% solutions of sanguinaria extract filtered at pH's of 3, 4, and 5 will form additional precipitates on standing with the minimum amount of precipitate forming at pH 3. This indicates that at pH's above 3 undesirable condensation and/or polymerization begins to occur.
The alkaloid extract when made into an oral rinse, dentifrice, or oral care product is an excellent breath freshener, and also an anti-plaque and anti-gingivitis agent. When combined with zinc chloride, however, the pH of the rinse needs to be acidic (pH=3) for a number of reasons. Zinc containing rinses are generally formulated at a pH of 3 for stability purposes as set forth in U.S. Patent 4,289,755. Other patent art teaches that higher pH's are attainable through the use of glycine. See U.S. Patent 4,339,432. Rinses at low pH's, especially with zinc chloride, also taste acrid.
In accordance with the present invention, novel mouthrinses containing sanguinaria extract of superior stability and improved uptake of sanguinaria into plaque, and improved protection against acid production by salivary bacteria, are attained by adjusting the pH of the rinses to 4.0 to 5.6, preferably 4.5, using selective buffer systems and by using emulsifiers with improved chemical compatibility with the extract. It was also discovered that impurities in emulsifiers can be detrimental to the stability of the extract. It was also shown that rinses at pH 4.5 can be used to significantly reduce malodor for a period of 8 hours when compared to a placebo rinse.
The oral rinse compositions of this invention are aqueous based. The compositions include one or more benzophenanthridine alkaloids and may also contain one or more zinc salts, if desired, such as zinc chloride. The benzophenanthridine alkaloids which are useful in the composition of this invention include sanguinarine, chelerythrine, sanguilutine, chelilutine, chelrubine, and sanguirubine.
It has now been found that the formation of precipitates in oral compositions containing benzophenanthridine alkaloids and zinc salts can be prevented by the use of a buffer system. A stable pH and precipitation-free composition which may contain zinc salts is provided in this invention.
Other useful zinc salts which may be included are, for example, zinc acetate, zinc gluconate, zinc sulfate, zinc salicylate, zinc tartrate, zinc lactate, zinc phenolsulfonate, and zinc carboxymethyloxysuccinate. Preferably the zinc salt is soluble in water in the amount present in the composition, although salts which are not water-soluble may also be used if they are properly suspended or emulsified. For example, see the zinc salts described in U.S. Patent 4,100,269.
The amount of zinc salt present may vary up to about 0.5% by weight e.g. 0.05 to 0.5% by weight. Preferably, if a zinc salt is used it is present in an amount of about 0.05 to 0.25% by weight.
The oral rinse compositions of this invention generally include, in addition to the benzophenanthridine alkaloid, about 50 to 95% by weight water (preferably about 75 to 90%); 5 to 25% by weight ethyl alcohol (preferably about 5 to 15%); 2 to 15% by weight of glycerine or other suitable humectant; 0.1 to 3.0% surface active agent (i.e. emulsifier); 0.02 to 1.0% by weight sweetening agent; 0.05 to 0.4% by weight flavoring agents; and 0 to 0.01% by weight coloring agents.
Other humectants suitable for this application include sorbitol, mannitol, propylene glycol, polyethylene glycols used individually or as combinations thereof. The function of these humectants are as texture, body, and flavor modifiers and as solubilizers.
The type of surface active agents suitable for this application include:
Anionics, such as sodium lauryl sulfates, sodium lauryl succinates, and sodium dodecylsulfonates.
Nonionics such as Polyoxyethylene sorbitan fatty acid esters, e.g. PEG (20) sorbitan isostearate, Polysorbate 20, Polysorbate 60, Polysorbate 80 and amine oxides, e.g. cocoamine oxide;
Amphoteric such as cocoamphocarboxypropionate and alkylbetaines, e.g. cocoamido betaines.
These surface active agents are used individually or in combinations thereof.
The type of sweetening agents suitable for this application include aspartame, acesulfame K, xylitol, sodium cyclamate, saccharin, and some humectants such as sorbitol, and mannitol. Flavoring agents used in the compositions of this invention should be free of sulfur compounds present in small amounts in natural mint oils such as pulegone, sabadine, and mercaptans.
The buffer system which is included in the oral rinse composition of the invention is preferably capable of maintaining the pH of the compositions in the desired range of about 4.0 to 5.6. In this pH range the stability of the compositions is very good, precipitates are avoided, and good uptake of alkaloid into plaque is attained.
There are a number of buffer systems which are useful in the compositions of the invention. When no zinc salts are present in the composition the following buffer systems are useful herein: Sodium Citrate/Citric Acid Sodium Acetate/Acetic Acid Sodium Tartrate/Tartaric Acid Sodium Phosphate/Phosphoric Acid Sodium Succinate/Succinic Acid Sodium Lactate/Lactic Acid Sodium Propionate/Propionic Acid.
When zinc salts are present in the composition, the useful buffer systems are as follows: Sodium Citrate/Citric Acid Sodium Acetate/Acetic Acid Sodium Tartrate/Tartaric Acid.
The invention is further illustrated by means of the following examples:
EXAMPLE I
An oral rinse composition was prepared using the ingredients listed below in the amounts stated: <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col1" align="left"><u style="single">Part</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">Ingredients</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">% by Weight</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">A</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">80.25</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">ZnCl₂</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Glycerin</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Sodium Saccharin</entry><entry namest="col3" nameend="col3" align="char" char=".">0.076</entry></row><row><entry namest="col1" nameend="col1" align="left">B</entry><entry namest="col2" nameend="col2" align="left">Ethyl-Alcohol 190 Proof</entry><entry namest="col3" nameend="col3" align="char" char=".">10.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Poloxamer 237</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Polysorbate 80</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Flavor</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" align="left">C</entry><entry namest="col2" nameend="col2" align="left">Buffer system:</entry><entry namest="col3" nameend="col3" /></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Tri Sodium Citrate 2H₂O</entry><entry namest="col3" nameend="col3" align="char" char=".">0.28</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Citric Acid Anhydrous</entry><entry namest="col3" nameend="col3" align="char" char=".">0.016</entry></row><row><entry namest="col1" nameend="col1" align="left">D</entry><entry namest="col2" nameend="col2" align="left">Fluid Extract (Sanguinaria)</entry><entry namest="col3" nameend="col3" /></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">1% Aqueous Solution</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" align="left">E</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char="."><u style="single">2.578</u></entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col3" align="char" char=".">100.00%</entry></row><row rowsep="1"><entry namest="col1" nameend="col3" align="justify">pH 4.48, 4.49.</entry></row></tbody></tgroup></table></tables> It is important to note that to achieve optimum stability of the rinse composition, the buffer system (part C) must be added to the rinse base (parts A and B) prior to the addition of the sanguinaria extract (part D) in order to avoid color changes and formation of precipitates.
Examples of other specific buffer systems which are useful in the compositions of this invention are illustrated in the following Examples II and III. <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col3" align="center"><u style="single">EXAMPLE II</u></entry></row><row><entry namest="col1" nameend="col1" align="left"><u style="single">Part</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">Ingredient</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">% W/W</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">A</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">80.25</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Zinc Chloride</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Glycerin</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Sodium Saccharin</entry><entry namest="col3" nameend="col3" align="char" char=".">0.076</entry></row><row><entry namest="col1" nameend="col1" align="left">B</entry><entry namest="col2" nameend="col2" align="left">Ethyl Alcohol 190 Proof</entry><entry namest="col3" nameend="col3" align="char" char=".">10.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Poloxamer 237¹</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Polysorbate 80²</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Flavor Oil</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" align="left">C</entry><entry namest="col2" nameend="col2" align="left">Sodium Acetate</entry><entry namest="col3" nameend="col3" align="char" char=".">1.09</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Acetic Acid, Glacial</entry><entry namest="col3" nameend="col3" align="char" char=".">0.10</entry></row><row><entry namest="col1" nameend="col1" align="left">D</entry><entry namest="col2" nameend="col2" align="left">Sanguinaria Extract Solution, 1%</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" align="left">E</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">1.684</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col3" align="char" char="."><o ostyle="single">100.00%</o></entry></row></tbody></tgroup></table></tables><tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col3" align="center"><u style="single">EXAMPLE III</u></entry></row><row><entry namest="col1" nameend="col1" align="left"><u style="single">Part</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">Ingredient</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">% W/W</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">A</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">80.25</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Zinc Chloride</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Glycerin</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Sodium Saccharin</entry><entry namest="col3" nameend="col3" align="char" char=".">0.076</entry></row><row><entry namest="col1" nameend="col1" align="left">B</entry><entry namest="col2" nameend="col2" align="left">Ethyl Alcohol 190 Proof</entry><entry namest="col3" nameend="col3" align="char" char=".">10.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Poloxamer 237¹</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Polysorbate 80²</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Flavor Oil</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" align="left">C</entry><entry namest="col2" nameend="col2" align="left">Sodium Tartrate</entry><entry namest="col3" nameend="col3" align="char" char=".">0.60</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Tartaric Acid</entry><entry namest="col3" nameend="col3" align="char" char=".">0.02</entry></row><row><entry namest="col1" nameend="col1" align="left">D</entry><entry namest="col2" nameend="col2" align="left">Sanguinaria Extract Solution, 1%</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" align="left">E</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">2.254</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col3" align="char" char="."><o ostyle="single">100.00%</o></entry></row></tbody></tgroup><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><tbody valign="top"><row><entry namest="col1" nameend="col3" align="justify">¹ Pluronic F-87, commercially available from BASF-Wyandotte is a polyoxyethylene, polyoxypropylene block polymer.</entry></row><row><entry namest="col1" nameend="col3" align="justify">² Tween 80, commercially available from ICI Americas is a mixture of oleate esters of sorbitol and sorbitol anhydrides consisting predominantly of monoesters, condensed with approximately 20 moles of ethylene oxide.</entry></row></tbody></tgroup></table></tables>
The oral rinses listed above are prepared in the following manner.
The part A ingredients are added to a main mixing vessel in the order listed, 5 minutes is allowed for mixing between each addition and a 15 minutes mixing when all of Part A has been added.
The part B ingredients are added to a separate mixing vessel in the order listed, 5 minutes being allowed for mixing between each addition and a 15 minutes mixing when all of part B has been added.
Part B is then added to part A in the main mixing vessel and mixed for 15 minutes.
Part C is dry blended and added to the main mixing vessel and mixed for 15 minutes. It is important to note that to achieve optimum stability of the rinse the buffers, "Part C", must be added to the rinse base prior to the addition of the Sanguinaria Extract Solution, part D. Color changes and precipitates may occur if this process is not followed.
Part D is added to the main mix vessel, followed by Part E which is used to rinse the Part D vessel.
After the addition of Part E the entire formula is mixed for 30 minutes and then passed through a filter having nominal pore size of 0.5 microns.
Another example of an oral rinse composition containing sanguinaria and zinc salt is as follows: <tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col3" align="center"><u style="single">EXAMPLE IV</u></entry></row><row><entry namest="col1" nameend="col1" align="left"><u style="single">Part</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">Ingredient</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">% W/W</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">A</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">80.25</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Zinc Chloride</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Sorbitol, 70</entry><entry namest="col3" nameend="col3" align="char" char=".">4.11</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Sodium Saccharin</entry><entry namest="col3" nameend="col3" align="char" char=".">0.076</entry></row><row><entry namest="col1" nameend="col1" align="left">B</entry><entry namest="col2" nameend="col2" align="left">Ethyl Alcohol 190 Proof</entry><entry namest="col3" nameend="col3" align="char" char=".">10.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Poloxamer 237¹</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Polysorbate 80²</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Flavor Oil</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" align="left">C</entry><entry namest="col2" nameend="col2" align="left">Tri Sodium Citrate 2H₂O</entry><entry namest="col3" nameend="col3" align="char" char=".">0.28</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Citric Acid Anhydrous</entry><entry namest="col3" nameend="col3" align="char" char=".">0.016</entry></row><row><entry namest="col1" nameend="col1" align="left">D</entry><entry namest="col2" nameend="col2" align="left">Sanguinaria Extract Solution, 1%</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" align="left">E</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">1.468</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col3" align="char" char="."><o ostyle="single">100.00%</o></entry></row></tbody></tgroup></table></tables> In order to maintain a stable pH and a precipitation free rinse containing Sanguinaria in the absence of zinc, the formulation and buffer system is not limited to previously mentioned examples.
Listed below is an additional formulation example in which there are no zinc salts present. <tables id="tabl0005" num="0005"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col3" align="center"><u style="single">EXAMPLE V</u></entry></row><row><entry namest="col1" nameend="col1" align="left"><u style="single">Part</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">Ingredient</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">% W/W</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">A</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">80.25</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Glycerin</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Sodium Saccharin</entry><entry namest="col3" nameend="col3" align="char" char=".">0.076</entry></row><row><entry namest="col1" nameend="col1" align="left">B</entry><entry namest="col2" nameend="col2" align="left">Ethyl Alcohol 190 Proof</entry><entry namest="col3" nameend="col3" align="char" char=".">10.00</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Poloxamer 237¹</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Polysorbate 80²</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Flavor Oil</entry><entry namest="col3" nameend="col3" align="char" char=".">0.20</entry></row><row><entry namest="col1" nameend="col1" align="left">C</entry><entry namest="col2" nameend="col2" align="left">Tri Sodium Citrate 2H₂O</entry><entry namest="col3" nameend="col3" align="char" char=".">0.10</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="left">Citric Acid Anhydrous</entry><entry namest="col3" nameend="col3" align="char" char=".">0.07</entry></row><row><entry namest="col1" nameend="col1" align="left">D</entry><entry namest="col2" nameend="col2" align="left">Sanguinaria Extract Solution, 1%</entry><entry namest="col3" nameend="col3" align="char" char=".">3.00</entry></row><row><entry namest="col1" nameend="col1" align="left">E</entry><entry namest="col2" nameend="col2" align="left">Purified Water</entry><entry namest="col3" nameend="col3" align="char" char=".">2.904</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col3" align="char" char="."><o ostyle="single">100.00%</o></entry></row></tbody></tgroup></table></tables> Other buffer system examples which can be substituted for the citrate buffers in Part C are as follows: Tartrate buffers Acetate buffers Phosphate buffers Succinate buffers Lactate buffers Propionate buffers. The oral rinses listed above are prepared using the same procedure previously discussed.
It has been found that sanguinaria extract becomes more chemically active as the pH is adjusted above three and can react with impurities that are present in some excipients used in the mouthrinse. For example a mouthrinse compositin that shows good chemical stability at a pH of 3.0 shows significant loss in sanguinarine content when the mouthrinse is adjusted to pH 4.5 to pH 5.5. As can be shown in the following example:
EXAMPLE VI
<tables id="tabl0006" num="0006"><table frame="all"><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm" /><colspec colnum="2" colname="col2" colwidth="39.37mm" /><colspec colnum="3" colname="col3" colwidth="39.37mm" /><colspec colnum="4" colname="col4" colwidth="39.37mm" /><thead valign="top"><row><entry namest="col1" nameend="col4" align="center"><u style="single">Stability of Sanguinaria in Rinses</u></entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col3" align="center"><u style="single">Initial</u></entry><entry namest="col4" nameend="col4" align="center"><u style="single">Aged 3 Months at 40°C</u></entry></row><row><entry namest="col1" nameend="col1" align="left"><u style="single">Wt% Poloxamer 407</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">pH</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">SaCl,*ppm</u></entry><entry namest="col4" nameend="col4" align="center"><u style="single">SaCl,ppm</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="char" char=".">0.1</entry><entry namest="col2" nameend="col2" align="char" char=".">2.7</entry><entry namest="col3" nameend="col3" align="right">100</entry><entry namest="col4" nameend="col4" align="right">73</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">0.1</entry><entry namest="col2" nameend="col2" align="char" char=".">4.5</entry><entry namest="col3" nameend="col3" align="right">99</entry><entry namest="col4" nameend="col4" align="right">58</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="char" char=".">0.1</entry><entry namest="col2" nameend="col2" align="char" char=".">5.0</entry><entry namest="col3" nameend="col3" align="right">109</entry><entry namest="col4" nameend="col4" align="right">33</entry></row></tbody></tgroup><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm" /><colspec colnum="2" colname="col2" colwidth="39.37mm" /><colspec colnum="3" colname="col3" colwidth="39.37mm" /><colspec colnum="4" colname="col4" colwidth="39.37mm" /><tbody valign="top"><row><entry namest="col1" nameend="col4" align="justify">*Sanguinarine chloride</entry></row></tbody></tgroup></table></tables>
In determining the reason for the loss of sanguinaria stability at elevated pH's it was unexpectedly found that this decreased stability at the elevated pH's was in part due to a surfactant (poloxamer 407). This nonionic surfactant is a block copolymer of polyoxyethylene and polyoxypropylene. The following data on mouthrinses formulated at pH 6.0 shows that as the concentration of poloxamer is increased in a mouthrinse the stability of sanguinaria decreases. <tables id="tabl0007" num="0007"><table frame="all"><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm" /><colspec colnum="2" colname="col2" colwidth="78.75mm" /><thead valign="top"><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center"><u style="single">3 Day Stability 40°C</u></entry></row><row><entry namest="col1" nameend="col1" align="center"><u style="single">Wt. % Poloxamer 407</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">SaCl,ppm</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="char" char=".">0.3</entry><entry namest="col2" nameend="col2" align="right">94</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">0.6</entry><entry namest="col2" nameend="col2" align="right">49</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="char" char=".">0.9</entry><entry namest="col2" nameend="col2" align="right">20</entry></row></tbody></tgroup></table></tables> Poloxamer 237 shows improved stability in rinses formulated at elevated pH's as shown by the following data: <tables id="tabl0008" num="0008"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm" /><colspec colnum="2" colname="col2" colwidth="31.50mm" /><colspec colnum="3" colname="col3" colwidth="31.50mm" /><colspec colnum="4" colname="col4" colwidth="31.50mm" /><colspec colnum="5" colname="col5" colwidth="31.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" /><entry namest="col3" nameend="col5" align="center"><u style="single">Stability at 40°C</u></entry></row><row><entry namest="col1" nameend="col1" align="left"><u style="single">0.1 Wt.% Poloxamer</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">ph</u></entry><entry namest="col3" nameend="col3" align="center"><u style="single">Initial</u></entry><entry namest="col4" nameend="col4" align="center"><u style="single">SaCl,ppm</u></entry><entry namest="col5" nameend="col5" align="center"><u style="single">Age-Weeks</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="right">407</entry><entry namest="col2" nameend="col2" align="char" char=".">4.5</entry><entry namest="col3" nameend="col3" align="right">101</entry><entry namest="col4" nameend="col4" align="right">45</entry><entry namest="col5" nameend="col5" align="right">10</entry></row><row><entry namest="col1" nameend="col1" align="right">407</entry><entry namest="col2" nameend="col2" align="char" char=".">5.0</entry><entry namest="col3" nameend="col3" align="right">106</entry><entry namest="col4" nameend="col4" align="right">40</entry><entry namest="col5" nameend="col5" align="right">10</entry></row><row><entry namest="col1" nameend="col1" align="right">237</entry><entry namest="col2" nameend="col2" align="char" char=".">4.5</entry><entry namest="col3" nameend="col3" align="right">92</entry><entry namest="col4" nameend="col4" align="right">77</entry><entry namest="col5" nameend="col5" align="right">13</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="right">237</entry><entry namest="col2" nameend="col2" align="char" char=".">5.2</entry><entry namest="col3" nameend="col3" align="right">95</entry><entry namest="col4" nameend="col4" align="right">71</entry><entry namest="col5" nameend="col5" align="right">13</entry></row></tbody></tgroup></table></tables> It was determined that the poloxamer 407 has a higher level of unsaturation than poloxamer 237 as shown in the following table: <tables id="tabl0009" num="0009"><table frame="all"><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm" /><colspec colnum="2" colname="col2" colwidth="78.75mm" /><thead valign="top"><row><entry namest="col1" nameend="col1" align="center"><u style="single">Surfactant</u></entry><entry namest="col2" nameend="col2" align="center"><u style="single">Unsaturation Meq/mg</u></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Poloxamer 407</entry><entry namest="col2" nameend="col2" align="right">48</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Poloxamer 237</entry><entry namest="col2" nameend="col2" align="right">34</entry></row></tbody></tgroup></table></tables> Unsaturation was determined by reacting methanolic mercuric acetate with the poloxamer, adding sodium bromide and then titrating the liberated acetic acid with methanolic potassium hydroxide.
EXAMPLE VII
The clinical efficacy of sanguinaria extract is due in part to its antimicrobial activity. Sanguinarine is known to inhibit 98% of the organisms found in dental plaque. (<u style="single">Antimicrobial Agents and Chemotherapy</u>, Apr. 1985, 27:4:663-665). Its MIC is generally 16 PPM or less for these organisms. It is known that sanguinarine extract is absorbed into plaque and onto oral soft and hard tissues (JADA Vol. 108, March 1984, p.338). It has now been discovered that by raising the pH of the mouthrinse from 3.0 to 4.5-5.6 there is an increased uptake of sanguinarine and total benzophenanthridine alkaloids into dental plaque as shown by the following table: <tables id="tabl0010" num="0010"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm" /><colspec colnum="2" colname="col2" colwidth="31.50mm" /><colspec colnum="3" colname="col3" colwidth="31.50mm" /><colspec colnum="4" colname="col4" colwidth="31.50mm" /><colspec colnum="5" colname="col5" colwidth="31.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col5" align="center">Sanguinarine and Total Benzophenanthridine Alkaloids Taken Into Wet Plaque from Mouthrinses</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">% SaCl</entry><entry namest="col2" nameend="col2" align="center">% ZnCl₂</entry><entry namest="col3" nameend="col3" align="center">pH</entry><entry namest="col4" nameend="col4" align="center">Sanguinarine ug/g wet plaque</entry><entry namest="col5" nameend="col5" align="center">Total Benzophenanthridine Alkaloids ug/g plaque</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="char" char=".">0.03</entry><entry namest="col2" nameend="col2" align="char" char=".">0.2</entry><entry namest="col3" nameend="col3" align="char" char=".">3.2</entry><entry namest="col4" nameend="col4" align="char" char=".">35.6</entry><entry namest="col5" nameend="col5" align="char" char=".">62.7</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">0.03</entry><entry namest="col2" nameend="col2" align="char" char=".">-</entry><entry namest="col3" nameend="col3" align="char" char=".">4.5</entry><entry namest="col4" nameend="col4" align="char" char=".">59.6</entry><entry namest="col5" nameend="col5" align="char" char=".">118.3</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">0.03</entry><entry namest="col2" nameend="col2" align="char" char=".">0.2</entry><entry namest="col3" nameend="col3" align="char" char=".">4.5</entry><entry namest="col4" nameend="col4" align="char" char=".">44.2</entry><entry namest="col5" nameend="col5" align="char" char=".">77.6</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">0.03</entry><entry namest="col2" nameend="col2" align="char" char=".">-</entry><entry namest="col3" nameend="col3" align="char" char=".">5.6</entry><entry namest="col4" nameend="col4" align="char" char=".">61.1</entry><entry namest="col5" nameend="col5" align="char" char=".">126.8</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="char" char=".">0.03</entry><entry namest="col2" nameend="col2" align="char" char=".">0.2</entry><entry namest="col3" nameend="col3" align="char" char=".">5.6</entry><entry namest="col4" nameend="col4" align="char" char=".">41.5</entry><entry namest="col5" nameend="col5" align="char" char=".">74.4</entry></row></tbody></tgroup></table></tables>
EXAMPLE VIII
In addition to measuring the uptake of sanguinaria extract into plaque, the efficacy of pH 3 and pH 4.5 rinses was measured using a modified saliva glucose test. An initial saliva sample was taken (background) and then subjects rinsed for one minute with a test rinse. The purpose of the back ground saliva sample was to measure shifts in the pH of the sample over time following the glucose challenge. One hour after rinsing with sanguinaria rinses with pH's adjusted to either pH 3.2 or pH 4.5 the saliva of the subjects was again collected under standard conditions. Glucose was then added to the background saliva samples and test saliva samples and the mixtures were incubated for three hours at 37°C. The pH's of these mixtures was monitored at 15, 30, 60, 120, and 300 minutes. Inhibition of salivary glycolysis was measured by subtracting the background pH reading at each timepoint from the test pH reading of the corresponding timepoint. Most of the background saliva samples rapidly decreased in pH after the addition of glucose. Thus, if the rinse treatment provides a protective effect the fall in pH is slow. The larger the differences, therefore, between the test and background pH, the better the inhibition of salivary glycolysis.
The following table shows that a treatment with a pH 4.5 rinse was more effective than treatment with a pH 3.2 rinse. The number of subjects was seven per group. The initial readings were used to adjust the outcome pH levels at each timepoint in order to test for differences between groups. The difference between the test rinses was statistically significant using analysis of covariance (ANCOVA) at a significance level of P .05. <tables id="tabl0011" num="0011"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col3" align="center">Inhibition of Salivary Glycolysis 5% Glucose added to Saliva Taken at Baseline and One Hour after Rinsing.</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">pH 4.5 Rinse</entry><entry namest="col3" nameend="col3" align="center">pH 3.2 Rinse</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Time (Minutes)</entry><entry namest="col2" nameend="col2" align="center">pH</entry><entry namest="col3" nameend="col3" align="center">pH</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="right">15</entry><entry namest="col2" nameend="col2" align="char" char=".">1.595</entry><entry namest="col3" nameend="col3" align="char" char=".">1.465</entry></row><row><entry namest="col1" nameend="col1" align="right">30</entry><entry namest="col2" nameend="col2" align="char" char=".">1.990</entry><entry namest="col3" nameend="col3" align="char" char=".">1.626</entry></row><row><entry namest="col1" nameend="col1" align="right">60</entry><entry namest="col2" nameend="col2" align="char" char=".">2.148</entry><entry namest="col3" nameend="col3" align="char" char=".">1.720</entry></row><row><entry namest="col1" nameend="col1" align="right">120</entry><entry namest="col2" nameend="col2" align="char" char=".">2.160</entry><entry namest="col3" nameend="col3" align="char" char=".">1.523</entry></row><row><entry namest="col1" nameend="col1" align="right">300</entry><entry namest="col2" nameend="col2" align="char" char=".">2.093</entry><entry namest="col3" nameend="col3" align="char" char=".">1.055</entry></row><row rowsep="1"><entry namest="col1" nameend="col3" align="justify">pH = Sample pH - Background pH at each time period.</entry></row></tbody></tgroup></table></tables>
Contents4
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO0071090A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| EP0565495A1 | Cited by | European Patent Office (EPO) | Search report |
| US8444958B2 | Cited by | United States of America | Applicant |
| WO2009010381A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| WO02067871A2 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US5073368A | Cited by | United States of America | Search report |
| EP0513544A1 | Cited by | European Patent Office (EPO) | Search report |
| WO9219242A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US9271906B2 | Cited by | United States of America | Applicant |
| US5425948A | Cited by | United States of America | Search report |
| TR27536A | Cited by | Türkiye | Search report |
| WO9414406A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| WO02067871A3 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| WO9219242A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US4376115A | Cites | United States of America | Search report |
22 members in 13 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 322659 | United States of America | – | |
| 32265989 | United States of America | A | |
| 322659 | – | – | – |
| US19890322659 | – | – | – |
Members22
| Document | Office | Kind | |
|---|---|---|---|
| NO901146D0 | Norway | D0 | |
| AU5128190A | Australia | A | |
| CA2011928A1 | Canada | A1 | |
| NO901146L | Norway | L | |
| EP0396232A2This record | European Patent Office (EPO) | A2 | |
| PT93385A | Portugal | A | |
| ZA901812B | South Africa | B | |
| JPH0314513A | Japan | A | |
| BR9001159A | Brazil | A | |
| EP0396232A3 | European Patent Office (EPO) | A3 | |
| US5066483A | United States of America | A | |
| NZ232572A | New Zealand | A | |
| AU632097B2 | Australia | B2 | |
| AR245591A1 | Argentina | A1 | |
| EP0396232B1 | European Patent Office (EPO) | B1 | |
| AT102016T | Austria | T | |
| ATE102016T1 | Austria | T1 | |
| DE69006899D1 | Germany | D1 | |
| DE69006899T2 | Germany | T2 | |
| NO176595B | Norway | B | |
| NO176595C | Norway | C | |
| PT93385B | Portugal | B |
38 legal events, as 3 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| It: last paid annual feeITTA | ITTA | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents actLapsedNLV1 | NLV1 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Fr: translation filedET | ET | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Main classification (correction)RHK1 | RHK1 | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0396232
- Publication, DOCDB
- 0396232
- Publication, EPODOC
- EP0396232
- Application
- 90302606
- Application, DOCDB
- 90302606
- Application, EPODOC
- EP19900302606
Titles3
- German
- Mittel zur oralen Spülung.
- English
- Oral rinse compositions.
- French
- Compositions de rinçage oral.
Classification
- CPC, 5
- A61K8/97
- A61K8/27
- A61K8/49
- A61K8/9789
- A61Q11/00
- IPC, 14
- A61K8 00
- A61K8 20
- A61K8 23
- A61K8 24
- A61K8 27
- A61K8 34
- A61K8 36
- A61K8 362
- A61K8 365
- A61K8 46
- A61K8 49
- A61K8 96
- A61K8 97
- A61Q11 00
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Denmark
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Netherlands (Kingdom of the)
- Sweden